1. Semester 1 Academic Session 2012/2013 ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering Universiti Malaysia Perlis

2. BIOPHARMACEUTICAL FACILITIES

3. The Drug Discovery, Development and Approval Process for Biopharmaceuticals (Biologics) DISCOVERY DEVELOPMENT LAUNCH Testing Phase Discovery / Preclinical Testing Test Population Laboratory and animals studies Purpose Assess safety biological activity and formulations Success Rate 5,000 compounds evaluated Manufacturin Activities Cell line construction, Cell banking Years 6.5 Approximate Cost $350M Clinical Trials Phase IPhase IIPhase III 20 to 100 healthy volunteers 100 to 500 patient volunteers 1,000 to 5,000 patient volunteers Determine safety and dosage Evaluate effectiveness, look for side effects Confirm effectiveness, monitor adverse reactions from long- term use 5 enter trials Process development, assay development, process optimization, scale-up, cGMP manufacture 1.5 23.5 $70M$100M$200M File application Review process / approval 1 approved Commercial manufacture 1.5 $80M Phase IV Additional post- marketing testing required by FDA =15 = $1B File NDA at FDA File IND at FDA

4. Research & Development (Pre-Clinical): Discovery Research, Bioinformatics, Lab Safety Quality: Quality Control & Assurance Operations: Process/Product, Development, Manufacturing & Production Clinical Research: Clinical Research, Regulatory Affairs Finance & Administration: Finance, Business Development, Administration, Information Systems, Legal, Facilities Management VP of Research/DevelopmentVP of OperationsDirection of QualityMedical DirectorVP of Finance & Administration Discovery Research Scientific Director Associate Scientific Director Principal Scientist Senior Scientist Scientist II Scientist I Senior Research Associate Research Associate Bioinformatics Scientist/Engineer Analyst/Programmer Molecular Modeler Lab Facilities Facility Manager/Supervisor (Animal Sciences) Veterinarian Lab Assistant/Glasswasher Process/Product Development Director of Process/Product Development Process Development Supervisor Process Development Associate Process Development Technician Manufacturing & Production Manufacturing Supervisor Manufacturing Associate Manufacturing Technician (Operator) Manufacturing Instrumentation/ Calibration Technician Quality Control (QC) Chemistry QC Analyst QC Technician Microbiology QC Analyst QC Technician Quality Assurance (QA) QA Manager/Supervisor QA Documentation Specialist QA Documentation Coordinator Clinical Research Manager Regulatory Affairs Manager of Regulatory Affairs Regulatory Affairs Associate Clinical Data Manager/Associate Finance Chief Financial Advisor Accounting Manager Accounting Clerk Administration Director of Human Resources Human Resources Representative Safety Manager Purchasing Agent/Buyer Receptionist Administrative Assistant Business Development Director of Business Development Legal Patent / IP Attorney Information Systems Manager of Information Systems Systems Analyst Analyst/Programmer Facilities Management Facilities Manager Facilities Technician Shipper/Receiver

5. Biomanufacturing upstream processing downstream processing quality control microbiologyquality control biochemistry Commercial scale biomanufacturing involves the building of a facility to produce the biopharmaceutical following upstream processing and downstream processing equipment and process SOPs. Samples are tested in quality control microbiology and quality control biochemistry laboratories to make sure the molecule has been produced correctly. cGMPs guide the process of manufacturing a biopharmaceutical and everything is documented. For ex: A new protein requires a facility to be prepared for its production and 400 to 600 individuals are hired, usually at least 50% are technicians. The largest bioreactor in such a facility is 25,000 liters. validation Once constructed and commissioned, the facility’s equipment and process SOPs must undergo validation. metrology facilities All instruments must be calibrated (instrumentation/calibration or metrology often part of facilities) and the set up, maintenance and use of each piece of equipment is logged. Environmental Health and Safety (EH&S) Environmental Health and Safety (EH&S) requirements are of central importance. (quality assurance) 21 CFR Part 210 and 211 is highly enforced during the making of an FDA approved protein for commercial production and widespread use (quality assurance).

6. Biopharmaceutical Manufacturing Departments Facilities/Metrology Validation Environmental Health and Safety (EH&S) QA Upstream Processing Downstream Processing QC Microbiology QC Biochemistry Process Development

7. Facilities in Gray Space

8. Facilities General Cleanroom Design HEPA filters in ceiling Exhaust vents on floor Seamless and rounded floor to wall junctions Readily accessible corners Floors, walls, and ceilings constructed of smooth hard surfaces that can be easily cleaned Limited equipment, fixtures and personnel Layout of equipment to optimize comfort and movement of operators Pressure Differentials between rooms Airlocks to control air balance

9. Facilities Production Clean Rooms

10. Facilities HEPA Filters High Efficiency Particulate Air Minimum particle collection efficiency: 99.97% for 0.3µm diameter particles. Disposable Filter made of pleated borosilicate glass microfiber

11. Biological Safety Cabinets Class 100

12. A microbiologist performing influenza research within a biosafety cabinet

13. Facilities Pressure Differentials Used to maintain airflow in the direction of higher cleanliness to adjacent less clean areas A minimum of 10-15 Pascals should be maintained between the aseptic area and an adjacent room with a different clean room classifications (doors open)

14. Facilities Airlocks Permit the passage of objects and people into a clean room. Consists of two airtight doors in series which do not open simultaneously.airtightdoors Spray down materials with 70% IPA before placing in the airlock

15. ISOPROPYL ALCOHOL  Powerful disinfectant and antiseptic  Mode of action: denatures proteins, dissolves lipids and can lead to cell membrane disintegration  Effectively kills bacteria and fungi  What is not killed by IPA? So, use what?  Why are aqueous solutions are preferred?

16. Gowning Certification

17. QC Microbiology – Environmental Monitoring Laser Particle Counter Air Samplers

18. Environmental (Air) Monitoring ParticlesViable Microbes (Bioburden) Microbial Air Sampler Laser Particle Counter

19. Environmental (Air) Monitoring Laser Particle Counter (particles/cubic meter) Microbial Air Sampler (colony forming units/ cubic meter) www.safety-epa.com/history_mold_air_sampling.htm

20. Utilities Water*: 200,000 to 300,000 liters of water are used per day in a commercial biopharmaceutical manufacturing facility. WFI: sand, diatomaceous earth, charcoal filter, water softener, RO, uv treatment, distillation, and constant circulate in a loop at 80 ⁰C. WFI piped to production equipment for CIP and SIP processes and for making media and buffers for production. DI and USP water used in QC labs (less pure); chilled potable water used for cooling. Gasses: Air, oxygen, and carbon dioxide to keep cells happy, nitrogen, and helium (to check for leaks in equipment).

21. HVAC: Heating, ventilation, and air conditioning in clean rooms and gray spaces. Waste*: Cells (sludge) - heat to very high temperatures and to sewer; liquids (media and buffers) treat with base and acid in a series of (three) tanks until neutral pH and to sewer. *Piped with 316L stainless dairy piping, triclover clamps, and valves.

24. Services for Drug Development Cell Banking and Characterization Product Characterization Process Characterization (Residual Testing) Vaccines and Cell Therapy Viral Clearance Stability Testing In Vivo Biosafety In Vivo and In Vitro Potency Testing Biosimilar Testing Discovery and Development Polyclonal Antisera Production Consulting and Project Management

25. VALIDATION PARAMETERS The following are validation parameters for key utilities and services GMP autoclaves. Overkill cycle, 60 minutes at 121°C at 15 psi. No survival of Bacillus stearothermophilus spores at a population of 10 6 Pure steam generator. Condensed pure steam meets USP WFI specifications. Endotoxin <0.125 EU/ml, and microbial content <1 Cfu/100 mL. Depyrogenation oven. 60 min. cycle at 250°C. <100 0.5 μm particles/ per ft 3 of 0.5 μm size. Minimum of 3 log endotoxin reduction. No survival of Bacillus subtilus at a population of 10 6. Ultra high quality water. <10 ppb of metals (such as Ni, Cu, and CO), <10 PPB of organics; <0.03 EU/mL of endotoxin; and <1Cfu/100mL. Resistivity 15-18 megohm. Meets and exceeds USP specifications for water for injection (WFI). HVAC and environmental baseline. Controlled areas except wash and microbial production (10,000 particles/ft 3 /min) and wash room and microbial production (100,000 particles/ft 3 /min). < 25 viable organisms/10 ft 3 of air; temperature 23±3°C; and humidity 40-60%.

26. Bench scale vs pilot For batch processes, in the pharmaceutical industry for example, bench scale is typically conducted on samples 1–20 kg or less, whereas pilot scale testing is performed with samples of 20–100 kg.

27. Pilot Plant – Overall Flow Plan

28. Biopharmaceutical Pilot plant General facility layout for a flexible, biopharmaceutical pilot facility with a 30,000-ft 2 area. AL = airlock; EN = entry airlock; EX = exit airlock;O = GMP depyrogenation oven; A = GMP autoclave; Utilities = UHQ water, pure steam, plant steam; Entry Corr = entry corridor to cell culture facility; Exit Corr = exit corridor from cell culture facility; QC = quality control; Mol Biol = molecular biology laboratory; RE = research laboratory entry/exit; PE = production facility entry/exit; PG = pregowning room; Jan = janitorial supply room; DR = dark room; PG = pregown room.

29. THANK YOU

30. Reference http://people.deas.harvard.edu/~jones/lab_arch/nano_facilities/hepa.gif http://news.thomasnet.com/images/large/451/451402.jpg www.bio-link.org Koichi, K., et al. Biopharmaceutical Manufacturing Facilities (2009). IHI Engineering Review, Vol 42, No. 2. http://www.bioasset.in/biopharmaceutical-service.html